TME PHARMA APPOINTS DIEDE VAN DEN OUDEN AS NEW CEO AT THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Berlin, Germany, June 25, 2025, 06.00 p.m. CEST – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Aram Mangasarian. The shareholders representing 16.67% of the total issued and outstanding share capital on May 28, 2025, were represented at the AGM which took place on June 25, 2025, at 03:00 p.m. CEST.

"On behalf of the Board and the entire TME Pharma *team I would like to welcome Diede van den Ouden as our new CEO. Diede's commitment to* TME Pharma, *demonstrated both as a significant shareholder and an active supporter, gives us great confidence as we enter this next chapter,"* said **Maurizio PetitBon, Chairman of TME Pharma**. *"I would also like to extend our heartfelt thanks to Aram for his invaluable leadership over the past years during which* TME Pharma *achieved tremendous advances, especially with regard to the industry-leading clinical data generated in glioblastoma – one of the most challenging areas in oncology***.** *We wish Aram the very best in his next venture and are pleased that he will stay involved with the TME R&D programs on an advisory basis. The Supervisory Board looks forward to working with Diede to continue driving our strategic objectives, including securing funding and partnerships for NOX-A12 and NOX-E36."*

"I am honored to join TME Pharma *at such a pivotal moment in the company's journey. Thanks to the dedication and vision of the entire team,* TME Pharma *has reached a critical inflection point, marked by robust clinical progress and a strengthened financial position, with reduced cash burn and a secured 12-month runway,"* said **Diede van den Ouden, the newly elected CEO of TME Pharma.** *"Building on this solid foundation, my focus will be on leading the company through its next phase of transformation, accelerating our strategic initiatives for both NOX-A12 and NOX-E36. As a major shareholder myself, my interests are fully aligned with those of our shareholders, and I am committed to delivering long-term value for all stakeholders."*

The full list of resolutions can be found below.

Item	**Resolution**
2.c. Adoption of the annual accounts 2024	Accepted
2.d. Release from liability of the sole member of the board of directors	Accepted
2.e. Release from liability of the members of the supervisory board	Accepted
3. Appointment of Diede Mink van den Ouden as sole member of the board of directors	Accepted
4. Re-appointment of Susan Coles as member of the supervisory board	Accepted
5. Amendment of the remuneration policy regarding the compensation structure of managing and supervisory board directors	Accepted

6. Appointment of Baker Tilly (Netherlands) B.V. as statutory auditor for the financial year 2025	Accepted
7. Partial amendment of the articles of association in relation to the increase of the authorized share capital	Accepted
8. Partial amendment of the articles of association in relation to re-instating a transitional provision to further increase the authorized share capital	Accepted
9. Renewal of the delegation to the board of directors to issue ordinary shares and/or preference shares and to limit or exclude any pre-emptive rights in connection therewith	Accepted
10. Renewal of the delegation to the board of directors to acquire shares	Accepted

The presentation outlining the agenda items and voting results of the AGM is available online. The minutes of the AGM will soon be made available on the company website.

For more information, please contact:

TME Pharma N.V.
Diede van den Ouden, CEO
Tel. +49 (0) 30 16637082 0
ir@tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma and *TME Pharma* was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in the United States. The company's second clinical-stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), showing potential to address fibrosis and inflammation is evaluated in

ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can be found at: www.tmepharma.com.

TME Pharma® and the *TME Pharma* logo are registered trademarks.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit *TME Pharma* on LinkedIn and X.

About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.